AM
REGENXBIO Pipeline
| Drug | Indication | Phase |
|---|---|---|
| RGX-314 | Wet Age-related Macular Degeneration (wAMD) | Phase 2 |
| RGX-202 | Duchenne Muscular Dystrophy (DMD) | Phase 1/2 |
| RGX-121 | Mucopolysaccharidosis Type II (MPS II, Hunter syndrome) | Phase 1/2 |
| RGX-181 | Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2 Disease) | Preclinical |
| RGX-381 | Ocular manifestations of FA Deficiency (FAD) | Phase 1/2 |
| ABBV-RGX-314 | Wet AMD & Diabetic Retinopathy | Phase 3 |
Leadership Team at REGENXBIO
KT
Kenneth T. Mills
President & Chief Executive Officer, Director
PJ
Patrick J. Christmas II, J.D.
Chief Legal Officer & Corporate Secretary
CM
Curran M. Simpson
Chief Operating Officer & Chief Technology Officer
DS
Dr. Steve Pakola
Chief Medical Officer
DO
Dr. Olivier Danos
Chief Scientific Officer (Senior Vice President)
VV
Vittal Vasista, CFA
Chief Financial Officer
DT
Dr. Timothy R. Miller
Co-Founder, Former President & CEO, Director
DJ
Dr. James M. Wilson
Co-Founder, Director, Head of Scientific Advisory Board
DK
Dr. Katherine A. High
Co-Founder, Director
DJ
Dr. Jeffrey S. Bartlett
Senior Vice President, Head of Technical Operations